Companies and AI developments
Updates
Daily market commentary, company analyses, investment stories and AI news. Price-only updates require a cumulative move of greater than 15% from the last published assessment. Newest first.
Optimistic scenario If Enbridge sustains roughly 5% DCF-per-share growth, funds its backlog without further material dilution and returns leverage to its target range, the three-year outcome could rest mainly on a growing dividend and stable valuation. The model also shows that even successful execution may deliver only a mid-single-digit to low-double-digit annual return if the market compresses the multiple. Read article →
Q3 2026 earnings Revenue grew 32%, adjusted EBITDA margin reached 19% and higher FY2026 guidance confirms operating leverage. Business strength rises to 6.8/10; at USD 32.85 attractiveness remains 3.0/10.
The Q3 call and filed 10-Q refine the recovery path: commercial cost trend remains above 11%, Medicaid margins are negative and OptumHealth’s 6–8% margin target extends to 2028. Company strength remains 7.2/10; the higher USD 405.40 entry price lowers attractiveness to 5.5/10.
Daily commentary Producer inflation keeps yields above five percent, while chips pay for uncertainty surrounding Nvidia Read article →
MFIC results sharpened the acquired portfolio's risk: NAV fell to USD 12.86, leverage was 1.43×, and nonaccruals remain elevated. ARCC strength stays 7.3/10; the higher price reduces attractiveness to 6.2/10.
The Q3 10-Q confirmed repayment of the remaining USD 428 million in cash without issuing shares and added SoFiUSD data. Scores and scenarios remain unchanged.
Daily commentary Five-percent bond yields and higher oil prices test equities, while companies deliver a mixed picture Read article →
Jensen Huang’s departure and Colette Kress’s interim appointment increase execution uncertainty and reduce business strength to 7.8/10. The lower USD 164.54 quote raises price attractiveness to 6.2/10 despite lower terminal prices in both scenarios.
ZETA rose 16.4% from the prior assessment to a $37.74 close, reducing the modeled base three-year return to 9.9% and price attractiveness to 3.5/10. Business strength remains 6.9/10; no new operating evidence was added.
The added Form 10-Q showed that loans 91–360 days past due were about 19.3% of the reported portfolio; the disclosure sharpens risk evidence but does not change business strength. At the $1,490.26 close, price attractiveness rises to 5.5/10.
Q3 2026 earnings Base44 approached $250 million of ARR, reached a 58% gross margin, and its first annual cohort renewed above management expectations. Lower nine-month FCF and reduced FCF-margin guidance limit the improvement in the assessment.
Q3 2026 earnings Revenue rose 49%, but subscribers declined sequentially, gross margin fell to 57%, and full-year adjusted EBITDA guidance was reduced. The $19.13 price also raises the modeled base three-year return to about 61%, while downside risk remains substantial.
Daily commentary AI rebound outweighed expensive money, Nvidia again highlights key-person risk Read article →
Q3 2026 earnings Growth excluding Marigold and political campaigns reached 30%, while customer KPIs, margins and FCF accelerated and management raised guidance. Business strength rose to 6.9/10; at the USD 32.42 close, price attractiveness is 4.2/10.
Daily commentary Hot CPI Raises the Cost of Money; CoreWeave Confirms Both Demand and Capital Risk Read article →
The $25 billion bond issuance confirms Microsoft's access to capital but adds interest claims, while Northern Trust demonstrates real agent use without disclosing the economics for Microsoft. Strength remains 8.4/10, and the higher $545.18 close reduces attractiveness to 5.9/10.
A new euro bond issuance and the Wyoming data-center plan confirm another capital-intensive expansion step and increase the importance of future cash returns; without new operating evidence, strength remains 7.8/10. Attractiveness remains 4.5/10 at the $283.93 close.
The Q3 10-Q and earnings call added evidence on shorter contracts, flat RPO and long-dated commitments to the strong growth picture, leaving company strength at 8.9/10. The lower $169.20 close improves scenario returns but raises attractiveness only to 2.3/10.
Daily commentary Cheaper Oil Lifted Wall Street; Today’s CPI Will Decide the Price of Money Read article →
Published a new analysis of Novo Nordisk (NVO).